Consensus Prothena Corporation plc

Stocks

PRTA

IE00B91XRN20

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:13:00 2026-08-04 EDT			5-day change	1st Jan Change
8.520 ^USD	+2.28%		-1.29%	-11.52%

06-05	Prothena Corp Public Ltd Insider Bought Shares Worth $465,295, According to a Recent SEC Filing	MT
06-03	Prothena Corp Public Ltd Insider Bought Shares Worth $471,300, According to a Recent SEC Filing	MT

Evolution of the Average Target: Prothena Corporation plc

Evolution of the Target Price: Prothena Corporation plc

Changes in Analyst Recommendations: Prothena Corporation plc

f46ec.JP1YmuoPzb183cFxyVScLoDGmdbNR0FWRG7ro4Au8ZA.Q54RyaNIko8Zi4oL-x_5T_Cl7uehLHYRIzi88N9di8J2qm7XhiKu4iS6sg~7697342fde9c18fbe667393e6fbc7e17

Analysts' recommendations: Prothena Corporation plc

02-20	RBC Raises Price Target on Prothena to $12 From $11, Keeps Sector Perform, Speculative Risk	MT
11-07	RBC Capital Adjusts Prothena Price Target to $11 From $10, Maintains Sector Perform Rating	MT
25-10-01	Prothena's partner Bristol Myers Squibb obtains fast track designation from US FDA for BMS-986446 for treatment of Alzheimer's disease	RE
25-08-05	RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk	MT
25-05-28	BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target	MT
25-05-27	Oppenheimer Downgrades Prothena to Market Perform From Outperform	MT
25-05-27	Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32	MT
25-05-27	Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating	MT
25-05-09	RBC Trims Price Target on Prothena to $18 From $20, Keeps Sector Perform, Speculative Risk	MT
25-02-21	RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk	MT
24-12-20	Chardan Initiates Coverage on Prothena With Buy Rating, $40 Price Target	MT
24-08-14	Oppenheimer Cuts Prothena Price Target to $62 From $66, Outperform Rating Maintained	MT
24-08-09	RBC Cuts Price Target on Prothena to $24 From $28, Keeps Sector Perform, Speculative Risk	MT
24-05-09	RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk	MT
24-02-20	Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating	MT
24-02-16	RBC Trims Price Target on Prothena to $35 From $36, Keeps Sector Perform, Speculative Risk	MT
24-01-25	RBC Cuts Price Target on Prothena to $36 From $43, Calls Initial Data on PRX012 'Anticlimactic,' Keeps Sector Perform, Speculative Risk	MT
23-12-12	Deutsche Bank Initiates Coverage on Prothena With Buy Rating, $62 Price Target	MT
23-11-02	RBC Cuts Price Target on Prothena to $43 From $60, Keeps Sector Perform, Speculative Risk	MT
23-08-04	JMP Securities Adjusts Prothena's Price Target to $83 From $82, Keeps Market Outperform Rating	MT
23-05-08	Cantor Fitzgerald Adjusts Prothena Price Target to $120 From $98, Maintains Overweight Rating	MT
23-05-05	HC Wainwright Adjusts Price Target on Prothena to $90 From $75, Maintains Buy Rating	MT
23-05-05	RBC Boosts Price Target on Prothena to $60 From $55, Maintains Sector Perform, Speculative Risk	MT
23-04-24	SVB Securities Starts Prothena at Outperform With $80 Price Target	MT
23-02-27	Citigroup Adjusts Price Target on Prothena to $72 From $76, Keeps Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROTHENA CORPORATION PLC					+156.9%
	WUXI APPTEC CO., LTD.					+27.23%
	ARGENX SE					+24.21%
	BIONTECH SE					+32.22%
	INSMED INCORPORATED					+99.04%
	GENMAB A/S					+29.58%
	PHARMAESSENTIA CORPORATION					-7.87%
	EXELIXIS, INC.					-5.1%
	ARROWHEAD PHARMACEUTICALS, INC.					+25.67%
	MADRIGAL PHARMACEUTICALS, INC.					+41.69%
	Average					+42.36%
	Weighted average by Cap.					+30.66%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.330USD

Average target price

21.40USD

Spread / Average Target

+156.90%

High Price Target

36.00USD

Spread / Highest target

+332.17%

Low Price Target

8.000USD

Spread / Lowest Target

-3.96%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
BofA Securities
Jefferies & Co.
Oppenheimer
Chardan Research
Deutsche Bank Securities
JMP Securities
Cantor Fitzgerald
HC Wainwright
SVB Securities LLC
Citigroup
Piper Sandler
Fox Advisors
BTIG